Abstract
Over the last decade, we have witnessed remarkable progress in the treatment of malignant melanoma. Success in treating this disease is inextricably linked to understanding the molecular processes involved in its pathogeneses and the identification of critical structures controlling the immune response.
Based on the results from clinical adjuvant studies, immunotherapy represented by checkpoint inhibitors (ipilimumab, pembrolizumab, and nivolumab), and targeted therapy (dabrafenib plus trametinib) in patients witn a proven BRAF gene mutation were gradually included in the treatment algorithms. The article summarizes the primary result of pivotal clinical trials and considers the possibilities of choosing the optimal treatment for the patient from the perspecitve of personal experience.